JP2023523429A5 - - Google Patents

Info

Publication number
JP2023523429A5
JP2023523429A5 JP2022564508A JP2022564508A JP2023523429A5 JP 2023523429 A5 JP2023523429 A5 JP 2023523429A5 JP 2022564508 A JP2022564508 A JP 2022564508A JP 2022564508 A JP2022564508 A JP 2022564508A JP 2023523429 A5 JP2023523429 A5 JP 2023523429A5
Authority
JP
Japan
Prior art keywords
cells
approximately
enriched
composition
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028504 external-priority patent/WO2021216790A1/en
Publication of JP2023523429A publication Critical patent/JP2023523429A/ja
Publication of JP2023523429A5 publication Critical patent/JP2023523429A5/ja
Pending legal-status Critical Current

Links

JP2022564508A 2020-04-22 2021-04-21 ナチュラルキラー(nk)細胞組成物およびそれを生成させるための方法 Pending JP2023523429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014056P 2020-04-22 2020-04-22
US63/014,056 2020-04-22
PCT/US2021/028504 WO2021216790A1 (en) 2020-04-22 2021-04-21 Natural killer (nk) cell compositions and methods for generating same

Publications (2)

Publication Number Publication Date
JP2023523429A JP2023523429A (ja) 2023-06-05
JP2023523429A5 true JP2023523429A5 (cg-RX-API-DMAC7.html) 2024-05-02

Family

ID=75787369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564508A Pending JP2023523429A (ja) 2020-04-22 2021-04-21 ナチュラルキラー(nk)細胞組成物およびそれを生成させるための方法

Country Status (8)

Country Link
US (1) US20230190801A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139439A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023523429A (cg-RX-API-DMAC7.html)
KR (1) KR20230088306A (cg-RX-API-DMAC7.html)
CN (1) CN116368221A (cg-RX-API-DMAC7.html)
AU (1) AU2021258194A1 (cg-RX-API-DMAC7.html)
CA (1) CA3180658A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021216790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
US20240002800A1 (en) * 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
CN115044552A (zh) * 2022-08-11 2022-09-13 启朔(北京)生物科技有限公司 一种自然杀伤细胞的体外培养方法及试剂盒
WO2024243058A1 (en) * 2023-05-19 2024-11-28 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and bendamustine
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
CA2300957A1 (en) 1997-08-15 1999-02-25 Rubicon Laboratory, Inc. Retrovirus and viral vectors
JP2001517454A (ja) 1997-09-19 2001-10-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
WO2001045737A2 (en) 1999-12-22 2001-06-28 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
CA2452517A1 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
WO2003082200A2 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
US20050220818A1 (en) 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
CA2498297A1 (en) 2002-09-09 2004-03-18 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
ATE539162T1 (de) 2003-03-27 2012-01-15 Ottawa Hospital Res Inst Mutierte viren der vesikulären stomatitis und deren verwendung
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
US8986672B2 (en) 2005-06-23 2015-03-24 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2008140621A2 (en) 2006-12-21 2008-11-20 Mount Sinai School Of Medicine Of New York University Transgenic oncolytic viruses and uses thereof
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
JP2010533718A (ja) 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009139921A2 (en) 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
CN112839666A (zh) * 2018-05-14 2021-05-25 因达普塔治疗公司 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
EP3884041A2 (en) * 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
KR20240051112A (ko) * 2021-07-01 2024-04-19 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 관련 방법

Similar Documents

Publication Publication Date Title
Wu et al. Developmental and functional control of natural killer cells by cytokines
Coates et al. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
KR100943087B1 (ko) 면역치료용 활성화 림프구 제조방법
JP2024527559A5 (cg-RX-API-DMAC7.html)
CN115558641B (zh) 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用
KR20220031541A (ko) 항-bcma car t 세포의 제조
CA3117134A1 (en) Ciml nk cells and methods therefor
CN115651903B (zh) 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用
TWI757785B (zh) 細胞激素誘導記憶型自然殺手細胞及其方法
JP2001149069A (ja) ナチュラルキラー細胞の増殖方法
AU2025204845A1 (en) Highly potent m-cenk cells and methods
US20040241153A1 (en) Methods of generating human cd4+ th1 cells
CN1444648A (zh) 扩增自然杀伤t细胞的方法
JPH08509859A (ja) TGF−βの中和による長期骨髄培養物における幹細胞の拡大
WO2025218187A1 (zh) 基因编辑的肿瘤浸润淋巴细胞和t细胞受体工程化t细胞及其在免疫治疗中的应用
AU782937B2 (en) Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same
US20240025990A1 (en) Prevention and treatment of graft-versus-host disease (gvhd)
US7429376B2 (en) Methods of screening for compounds that improve engraftment
RU2851449C1 (ru) Новое лечение сепсиса
CN117120596A (zh) 高效的m-cenk细胞和方法
Li A study of human mast cell origin and differentiation
김병수 The Role of Regulatory T Cells Expanded by Anti-DR3 Antibody for Alleviation of Acute Graft-versus-Host Disease
Blaser Interleukin 15 and transplantation biology: the interface of innate and adaptive immunity
HK1240616A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions